Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Senju Gearing Up to Grow Lucentis Biosimilar into Its Mainstay Product
Senju Pharmaceutical aims to promote and grow its biosimilar version of the VEGF inhibitor Lucentis into its major product. Since it will be Japan’s first biosimilar in the field of ophthalmology, the company will initially focus on familiarizing ophthalmologists with…
To read the full story
Related Article
- Lucentis, Rituxan Biosimilars Win Label Expansions
September 28, 2023
- Lucentis Biosimilar Now Approved for Diabetic Macular Edema
January 16, 2023
- 1st Lucentis Biosimilar Launched in Japan, Senju Eyes 6.9 Billion Yen in 5th Year
December 10, 2021
BUSINESS
- Santen Snags China Rights to 5 Glaucoma Drugs from AbbVie
April 20, 2026
- AbbVie Launches Aquipta Migraine Drug in Japan
April 20, 2026
- Fronteo, Astellas Partner on AI-Driven Drug Target Discovery
April 20, 2026
- Towa to Outsource 1.5 Billion Tablets to Adragos by 2033
April 20, 2026
- Lilly’s Omvoh 200 mg SC Wins Japan Nod for UC Maintenance Use
April 17, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…